FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information 1 INDICATIONS AND USAGE 1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use LOVAZA periodically during therapy. (5.1)safely and effectively. GSKSOURCE.COMTRANSLATE THIS PAGE wOFF [ ¡@ FFTM € jUÂðGDEF œ OS/2 ¼C`g§K„cmap rJð šcvt ( ‡fpgm $ ± eS´/§gasp Ø glyf àN ‰ 3!headRì46 bXþhheaS $ 2 hmtxS ôÁÁ ŽlocaTP « ¸4 VNmaxpUü nameV ‚ |Ô¯™ípostW @ „¹F¦iprepZà..°ò+ webf[ X¯Ræ Ì=¢ÏÏ òÏ .xÚc`d``à b `b` Â[@Ì æ1 ¨ xÚc`fidœÀÀÊÀÂÌÃt ! TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. HIGHLIGHTS OF PRESCRIBING INFORMATION BECAUSE TRIUMEQ … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TRIUMEQ safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION • AVODART. … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use AVODART safely and effectively. See fu ll prescribing information for FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information 1 INDICATIONS AND USAGE 1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use LOVAZA periodically during therapy. (5.1)safely and effectively. GSKSOURCE.COMTRANSLATE THIS PAGE wOFF [ ¡@ FFTM € jUÂðGDEF œ OS/2 ¼C`g§K„cmap rJð šcvt ( ‡fpgm $ ± eS´/§gasp Ø glyf àN ‰ 3!headRì46 bXþhheaS $ 2 hmtxS ôÁÁ ŽlocaTP « ¸4 VNmaxpUü nameV ‚ |Ô¯™ípostW @ „¹F¦iprepZà..°ò+ webf[ X¯Ræ Ì=¢ÏÏ òÏ .xÚc`d``à b `b` Â[@Ì æ1 ¨ xÚc`fidœÀÀÊÀÂÌÃt ! TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. HIGHLIGHTS OF PRESCRIBING INFORMATION BECAUSE TRIUMEQ … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TRIUMEQ safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION • AVODART. … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use AVODART safely and effectively. See fu ll prescribing information for FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information 1 INDICATIONS AND USAGE 1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use LOVAZA periodically during therapy. (5.1)safely and effectively. GSKSOURCE.COMTRANSLATE THIS PAGE wOFF [ ¡@ FFTM € jUÂðGDEF œ OS/2 ¼C`g§K„cmap rJð šcvt ( ‡fpgm $ ± eS´/§gasp Ø glyf àN ‰ 3!headRì46 bXþhheaS $ 2 hmtxS ôÁÁ ŽlocaTP « ¸4 VNmaxpUü nameV ‚ |Ô¯™ípostW @ „¹F¦iprepZà..°ò+ webf[ X¯Ræ Ì=¢ÏÏ òÏ .xÚc`d``à b `b` Â[@Ì æ1 ¨ xÚc`fidœÀÀÊÀÂÌÃt ! TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. HIGHLIGHTS OF PRESCRIBING INFORMATION BECAUSE TRIUMEQ … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TRIUMEQ safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION • AVODART. … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use AVODART safely and effectively. See fu ll prescribing information for FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information 1 INDICATIONS AND USAGE 1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use LOVAZA periodically during therapy. (5.1)safely and effectively. GSKSOURCE.COMTRANSLATE THIS PAGE wOFF [ ¡@ FFTM € jUÂðGDEF œ OS/2 ¼C`g§K„cmap rJð šcvt ( ‡fpgm $ ± eS´/§gasp Ø glyf àN ‰ 3!headRì46 bXþhheaS $ 2 hmtxS ôÁÁ ŽlocaTP « ¸4 VNmaxpUü nameV ‚ |Ô¯™ípostW @ „¹F¦iprepZà..°ò+ webf[ X¯Ræ Ì=¢ÏÏ òÏ .xÚc`d``à b `b` Â[@Ì æ1 ¨ xÚc`fidœÀÀÊÀÂÌÃt ! TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. HIGHLIGHTS OF PRESCRIBING INFORMATION • AVODART. … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use AVODART safely and effectively. See fu ll prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION BECAUSE TRIUMEQ … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TRIUMEQ safely and effectively. See full prescribing information for FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information 1 INDICATIONS AND USAGE 1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use LOVAZA periodically during therapy. (5.1)safely and effectively. GSKSOURCE.COMTRANSLATE THIS PAGE wOFF [ ¡@ FFTM € jUÂðGDEF œ OS/2 ¼C`g§K„cmap rJð šcvt ( ‡fpgm $ ± eS´/§gasp Ø glyf àN ‰ 3!headRì46 bXþhheaS $ 2 hmtxS ôÁÁ ŽlocaTP « ¸4 VNmaxpUü nameV ‚ |Ô¯™ípostW @ „¹F¦iprepZà..°ò+ webf[ X¯Ræ Ì=¢ÏÏ òÏ .xÚc`d``à b `b` Â[@Ì æ1 ¨ xÚc`fidœÀÀÊÀÂÌÃt ! TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. HIGHLIGHTS OF PRESCRIBING INFORMATION • AVODART. … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use AVODART safely and effectively. See fu ll prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION BECAUSE TRIUMEQ … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TRIUMEQ safely and effectively. See full prescribing information for FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information 1 INDICATIONS AND USAGE 1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use LOVAZA periodically during therapy. (5.1)safely and effectively. GSKSOURCE.COMTRANSLATE THIS PAGE wOFF [ ¡@ FFTM € jUÂðGDEF œ OS/2 ¼C`g§K„cmap rJð šcvt ( ‡fpgm $ ± eS´/§gasp Ø glyf àN ‰ 3!headRì46 bXþhheaS $ 2 hmtxS ôÁÁ ŽlocaTP « ¸4 VNmaxpUü nameV ‚ |Ô¯™ípostW @ „¹F¦iprepZà..°ò+ webf[ X¯Ræ Ì=¢ÏÏ òÏ .xÚc`d``à b `b` Â[@Ì æ1 ¨ xÚc`fidœÀÀÊÀÂÌÃt ! TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. HIGHLIGHTS OF PRESCRIBING INFORMATION • AVODART. … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use AVODART safely and effectively. See fu ll prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION BECAUSE TRIUMEQ … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TRIUMEQ safely and effectively. See full prescribing information for FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information 1 INDICATIONS AND USAGE 1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use LOVAZA periodically during therapy. (5.1)safely and effectively. GSKSOURCE.COMTRANSLATE THIS PAGE wOFF [ ¡@ FFTM € jUÂðGDEF œ OS/2 ¼C`g§K„cmap rJð šcvt ( ‡fpgm $ ± eS´/§gasp Ø glyf àN ‰ 3!headRì46 bXþhheaS $ 2 hmtxS ôÁÁ ŽlocaTP « ¸4 VNmaxpUü nameV ‚ |Ô¯™ípostW @ „¹F¦iprepZà..°ò+ webf[ X¯Ræ Ì=¢ÏÏ òÏ .xÚc`d``à b `b` Â[@Ì æ1 ¨ xÚc`fidœÀÀÊÀÂÌÃt ! TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. HIGHLIGHTS OF PRESCRIBING INFORMATION • AVODART. … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use AVODART safely and effectively. See fu ll prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION BECAUSE TRIUMEQ … 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TRIUMEQ safely and effectively. See full prescribing information for FLOVENT HFA IS INDICATED FOR THE MAINTENANCE TREATMENT OF 1 HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use FLOVENT HFA safely and effectively. See full prescribing information TANZEUM IS CONTRAINDICATED IN PATIENTS WI 3 2 DOSAGE AND ADMINISTRATION 2.1 Dosage The recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. For US Healthcare Professionals
GSK MedInfo
Menu
Close
Close
Login Register
Your browser does not support JavaScript. Some components may not be visible.
Basket
User logged in
Overlay Text
* GSK Products
* Therapy Areas
* Resources
* Webinars
* Contact Us
* Basket 0
* GSK MedInfo
_Registration successful_ You now have access to the latest updates, events and resources. Event _Registration successful_ You now have sucesfully register for the event and you can also access the latest updates, events and resources. In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number. _Account activated – pending validation._ Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next days. In the meantime, you can enjoy access to all the latest news, events and resources on our website _EVENT REGISTRATION COMPLETED - PENDING VALIDATION._ Your account has been activated successfully, but we still need to validate you as a healthcare professional. We'll send you and email with the result of the validation process in the next days. In the meantime, you can enjoy access to all the latest news, events and resources on our website In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here .
_Account activated - pending validation._ Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next days. In the meantime, you can enjoy the public content on our website _Event Account activated - pending validation._ Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next days. In the meantime, you can enjoy the public content on our website In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here .
already registered
X »
$previewUrl
ANORO ELLIPTA 20 MCG has been lorem added to your basket View Basket
60
Unit for Hours:hour
Unit for Minutes: M
Loading text: $loading Filter redirection page URL: events-3-3.html Login overlay needed?: true Filter Tags:Medical indications|Products|Therapy Area Filter Tags values when filtered by all Tags:All Therapy Areas OutofBox filter category name:Format Filter Reset all button text:Reset All Filter Apply button text:Apply Events registration success message: Registration successfull Events registration failure message: Registration failure Events un-registration success message: Un-Registration successfull Events un-registration failure message: Un-Registration failure Reset all default value: false Show More Naivagation Values: 10|25|50 Previous Text label: Previous Next Text label: Next Show Text label: Show: Seats left Text: spaces left No Seats left Text: No spaces left Text Area Blank copy in Email Template:Not Provided See speaker bio text: See Speaker Bio Next text: NEXT:
See all dates text: See all dates/times LEAVING GSK PRO
You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites. Continue
Cancel
Month Names:$MonthNames Day Names:$dayNameShort Popup
4
MEDICAL EDUCATION
Take advantage of GSK product and disease state webinars to increase your medical knowledge. View Topics
REQUEST SAMPLES AND SAVINGS OFFERS Provide your NPI# to see what is available for you. Check Availability
Products
FIND PRODUCT INFORMATION Access the most up-to-date prescribing information and supporting details for many of our products. View Product List
On Demand
LEARN ON YOUR OWN TIME GSK Medical Science Liaisons offer on-demand medical education you can watch whenever you’re ready. Watch Now
Patient Assistance
HELP ELIGIBLE PATIENTS ACCESS GSK MEDICINES Find patient assistance programs and reimbursement support to help eligible patients access GSK prescription medicines and vaccines. Find Programs
_Look For Updated Vaccines Packaging_ We are updating the outer carton design to harmonize the look and feel across the GSK Vaccines portfolio. View Updated Packaging Resources
FOR YOU AND YOUR PATIENTS Find handouts and other materials to help your patients understand and follow their treatment plan. View Resources
REGISTER FOR GSKPRO
Get exclusive access to educational programs & patient care resources. Sign Up Now
Therapy Areas
EXPAND YOUR KNOWLEDGE We offer disease-related information in major therapy areas addressed by our portfolio of products. Explore Therapy Areas TOP RESOURCES
VACCINE CODING GUIDE Download Summary Sheet (PDF) HOW LUPUS AFFECTS THE BODY Download Lupus Worksheet (PDF) EHR RESOURCES
View Resource Guides NAWCNT190024 July 2019 Contact us
GSK Response Center: 1-888-593-5977 Vaccine Service Center: 1-866-475-8222 GSK Medical Information: 1-877-GSK-MI4U (1-877-475-6448)
REQUEST A CALLBACK
* Live chat
* Gsk.com
* Change Country
* Sitemap
* Legal Notice
* Privacy Notice
* Interest-based Ads To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967. Trademarks are owned by or licensed to the GSK group of companies. This site is intended for US healthcare professionals only. ©2020 GSK or licensor. NAWCNT200004 August 2020. SORRY, THIS SITE IS NOT SUPPORTED ON ANDROID V4.3 AND BELOW. Please update your operating system or use a different device. Chat